ClinicalTrials.Veeva

Menu

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

W

Watson Pharmaceuticals

Status and phase

Completed
Phase 4

Conditions

Menopause

Treatments

Drug: Premarin® (oral) vs. Alora® (transdermal)

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00224094
ALO0102

Details and patient eligibility

About

This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.

Enrollment

27 patients

Sex

Female

Ages

42 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy
  • Naturally menopausal women
  • Aged 42-70 years
  • Currently using combination estrogen-progestin replacement therapy

Exclusion criteria

  • Women with contraindications to HRT use, including:Unexplained vaginal bleeding, liver disease, breast or endometrial cancer, venous thromboembolic events
  • Thyroid disease
  • Adrenal disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

27 participants in 2 patient groups

Sequence A
Experimental group
Description:
Oral ERT then transdermal ERT
Treatment:
Drug: Premarin® (oral) vs. Alora® (transdermal)
Sequence B
Experimental group
Description:
Transdermal ERT then oral ERT
Treatment:
Drug: Premarin® (oral) vs. Alora® (transdermal)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems